Bioconversion of lovastatin to simvastatin by Streptomyces carpaticus toward the inhibition of HMG‐CoA activity
Biotechnology and Applied Biochemistry · 2023
DOI: 10.1002/bab.2429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2023. Verfasst von Janani Balraj und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India. Hauptthemen laut MEDLINE: Lovastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Department of Science and Technology, DST FIST.
Abstract (Originalsprache)
The aim of this study was the modification of lovastatin by microbes to improve its potential. Actinobacteria exhibit staggering diversity in terms of their biosynthetic capability for specialized metabolites which has been traced back to the presence of specialized gene clusters. The objective of the study is to exploit the potential of Actinobacteria strain(s), which can biotransform lovastatin to simvastatin, which might be a more potent therapeutic agent than lovastatin. We have screened 40 Actinobacteria strains and assessed their biotransformation potential primarily through thin layer chromatography (TLC) analysis, followed by high performance thin layer chromatography and high performance liquid chromatography analysis. One strain C7 (CTL S12) has been identified as a potential Actinobacteria that favored the simvastatin biotransformation. The morphological and biochemical analysis together with 16S rRNA sequencing coupled with phylogenetic analysis confirmed the ideal strain (C7) as Streptomyces carpaticus . Successively, the purified simvastatin from S. carpaticus was characterized by liquid chromatography–mass spectrometry (LC–MS), infrared spectrometry, nuclear magnetic resonance, and HMG‐CoA assay. In the LC–MS analysis, a peak at 419.24 m/z confirmed the elemental composition of simvastatin (C 25 H 39 O 5 ). In HMG‐CoA assay, the IC50 of simvastatin was 50 μg/ml, and the inhibitory potential was 1.36 times higher compared to that of lovastatin. Thus, the biotransformation of simvastatin from lovastatin by S. carpaticus is reported for the first time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbial Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India.
- Bharathiar Cancer Theranostics Research Centre, RUSA2.0, 641046, Bharathiar University, Coimbatore, Tamil Nadu, India.
- Centre for Plant Tissue Culture and Central Instrumentation Laboratory, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
- Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
- Dean-Research, Marudupandiyar college, 613403, Thanjavur, Tamil Nadu, India.
ORCID-Profile: Angayarkanni Jayaraman
Förderung
- Department of Science and Technology
- DST FIST
Zitieren
APA
Balraj, J., Murugesan, T., Dhanapal, A. R., Kalieswaran, V., Jairaman, K., Archunan, G., & Jayaraman, A. (2023). Bioconversion of lovastatin to simvastatin by Streptomyces carpaticus toward the inhibition of HMG‐CoA activity. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2429
Vancouver
Balraj J, Murugesan T, Dhanapal AR, Kalieswaran V, Jairaman K, Archunan G, et al. Bioconversion of lovastatin to simvastatin by Streptomyces carpaticus toward the inhibition of HMG‐CoA activity. Biotechnology and Applied Biochemistry. 2023. doi:10.1002/bab.2429
BibTeX
@article{Balraj2023,
author = {Balraj, Janani and Murugesan, Thandeeswaran and Dhanapal, Anand Raj and Kalieswaran, Vidhya and Jairaman, Karunyadevi and Archunan, Govindaraju and Jayaraman, Angayarkanni},
title = {Bioconversion of lovastatin to simvastatin by Streptomyces carpaticus toward the inhibition of HMG‐CoA activity},
journal = {Biotechnology and Applied Biochemistry},
year = {2023},
doi = {10.1002/bab.2429}
}
EUVIMED